Latest news with #Wegov
North Wales Chronicle
5 days ago
- Health
- North Wales Chronicle
High demand expected for new daily weight loss pill
Pharmaceutical company Eli Lilly said it expects substantial demand when the new pill is launched. Lilly said it will seek approval by international regulators as it published the results of a large study into orforglipron. The new pill is a GLP-1 agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite. The manufacturer also makes Mounjaro, dubbed the King Kong of weight loss jabs. Weight loss jabs have been hailed as transformative by health leaders. But injections come with additional work for over-stretched health services so tablet forms of medication, which are expected to be cheaper and easier to use, may offer a new hope for the millions of people looking to lose weight. The new study data on orforglipron showed that people taking the drug lost an average of 12.3 kilograms while taking the drug for 72 weeks compared with those not taking the drug. Three in five (60%) of people taking the highest dose of orforglipron lost at least 10% of their body weight, while 40% lost at least 15% of their body weight, according to the study, which is to be presented to the European Association for the Study of Diabetes (EASD) Annual Meeting 2025. A once-a-day pill to treat obesity could be a game-changer. Today we announced positive results of a late-stage clinical trial studying a once-daily oral medicine for obesity. Read more: — Eli Lilly and Company (@EliLillyandCo) August 7, 2025 In addition to weight loss the people in the study also showed other health benefits, including improvements in cholesterol, blood pressure and heart disease risk. Experts highlighted how the tablet did not appear to yield the same benefits as some weight loss jabs, but said they will be more 'tolerable' for many patients. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most commonly reported side effect. The pill was assessed in a study of 3,127 adults who were obese or overweight, with a weight-related medical problem and without diabetes. 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,' said Lilly's Kenneth Custer. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients. 'The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.' It comes as a separate study highlighted the potential other benefits of using GLP-1s, also known as glucagon-like peptide 1 receptor-agonists. They were initially developed as a treatment for people with type 2 diabetes and are now widely used to treat obesity and help people lose weight. The separate paper, from McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss by looking at trials which had assessed the drugs in other areas of medicine. Writing in the journal eClinicalMedicine, experts said GLP-1s may also play a role in improving liver disease; sleep apnoea; arthritis of the knee; polycystic ovary syndrome; Parkinson's disease; Alzheimer's disease and substance misuse. But they also highlighted potential safety issues linked to the drugs including potential issues with the pancreas and gall bladder. 'The therapeutic landscape for obesity and related metabolic conditions has evolved substantially with the emergence of GLP-1 RAs,' they wrote. 'These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders. 'As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centred treatment strategies.'
Time of India
30-04-2025
- Health
- Time of India
Wegovy is now just a click away: What you should know about this popular weight loss drug and the red flags
Novo Nordisk's Wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449. Novo Nordisk , the makers of the weight loss drug Wegovy , have announced that the medication will soon be available for purchase for US customers through telehealth companies such as Hims & Hers Health, Inc., LifeMD, and Ro. This means people who want to have access to the weight loss drug, but were lacking insurance coverage, can now buy it for a reduced price of $449 per month. The drug will be available in the same auto-inject pens. As more people would be reaching out for the drug, it is important to know more about the drug and also its possible side effects. (Pic courtesy: iStock) What is Wegovy? by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Invest $200 in Amazon without buying stocks to earn a second salary Marketsall Sign Up Undo Wegovy is a prescription drug used to aid weight loss. It belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. The semaglutide injection, when combined with a calorie-deficient diet and increased exercise, would result in weight loss. This drug works by reducing your appetite and slowing down the rate at which food moves from your stomach to your intestines. This way, you feel fuller for a longer time, and it also helps reduce your blood sugar levels. Available as a 2.4 mg injectable, this drug reduces the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. It can also help adults and children aged 12 and older manage weight and fight obesity and overweight-related problems. Demi Lovato's Dramatic Transformation Stuns Fans: Ozempic Whispers Grow Louder | Watch What are the side effects of Wegovy? Like most drugs, Wegovy could also result in undesirable side effects. This can range from mild to serious. The drug makers have cautioned people with thyroid cancer or a family history to not use the medication, as it may cause thyroid tumours, including cancer. People who have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are also advised not to use the drug. FILE - Donna Cooper holds up a dosage of Wegovy, a drug used for weight loss, at her home in Front Royal, Va., on Friday, March 1, 2024. (AP Photo/Amanda Andrade-Rhoades, File) People who have or have had problems with their pancreas or kidneys should talk to their health provider before using the drug. The same goes for type 2 diabetes, those with a history of diabetic retinopathy, depression, suicidal thoughts, mental health issues, scheduled surgery, or other procedures that use anesthesia or deep sedation. Pregnant women and those who plan to get pregnant are also advised to talk to their doctor. 'Wegovy may harm your unborn baby. You should stop using Wegovy 2 months before you plan to become pregnant,' the company warns. Also, women who are breastfeeding or plan to, should know that the drug passes into the breast milk. Common side effects of Wegovy include: nausea diarrhea vomiting constipation stomach (abdomen) pain headache tiredness (fatigue) upset stomach dizziness feeling bloated belching low blood sugar in people with type 2 diabetes gas stomach flu heartburn runny nose or sore throat Some of the serious possible side effects of Wegovy include: inflammation of the pancreas (pancreatitis) gallbladder problems increased risk of low blood sugar (hypoglycemia), especially in people who are on diabetes medications such as insulin or sulfonylureas kidney problems (kidney failure) severe stomach problems serious allergic reactions such as swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat change in vision in people with type 2 diabetes increased heart rate depression or thoughts of suicide food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation
